/
/
/

Skybiotech Healthcare Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
---0%
---0%
-30%-1%-33%
-26%-26%-26%-26%

Peer Comparison

Symbol
KPRMILL-A
PAGEIND-A
WELSPUNLIV-A
VTL-A
ARVIND-A
MANYAVAR-A
PGIL-A
ICIL-A
SWANCORP-A
GARFIBRES-A
SKYBIOTECH-X
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,174.45₹39613 Cr38.1110.0936.86₹867 Cr
35,680₹39310 Cr52.01172.86775.02₹764 Cr
265.9₹23931 Cr55.171.798.91₹204 Cr
522₹14779 Cr17.4310.745.91₹745 Cr
507.05₹13643 Cr29.755.4429.71₹414 Cr
499.9₹12059 Cr31.253.3222.96₹376 Cr
1,305.1₹11780 Cr37.9610.8843.63₹278 Cr
479.35₹9254 Cr61.333.1916.03₹127 Cr
243.95₹7606 Cr34.02-111.1₹274 Cr
742.35₹7237 Cr30.58628.08₹199 Cr
115₹22 Cr—-3-6.31-₹1 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
₹49 L₹2 Cr₹96 L₹2 Cr₹2 Cr₹1 Cr₹3 Cr₹2 Cr₹0₹0
₹6 L₹15 L₹8 L₹4 L₹4 L-₹18 L₹15 L₹4 L₹35 L₹60 L
₹55 L₹2 Cr₹1 Cr₹2 Cr₹2 Cr₹84 L₹3 Cr₹2 Cr₹35 L₹60 L
₹1 Cr₹3 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹3 Cr₹2 Cr₹4 L₹2 L
-₹46 L-₹73 L-₹36 L-₹19 L₹11 L-₹1 Cr-₹16 L₹7 L₹31 L₹58 L
₹40,000₹50,000₹40,000₹50,000₹70,000-₹23 L₹11 L₹14 L₹0₹0
-₹57 L-₹85 L-₹49 L-₹31 L-₹2 L-₹1 Cr-₹41 L-₹19 L₹31 L₹58 L
-₹57 L-₹30 L-₹49 L-₹31 L-₹2 L-₹1 Cr-₹39 L-₹25 L₹25 L₹49 L

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Unsecured Loans
Deferred Tax Assets / Liabilities
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2025
—
₹2 Cr
₹7 Cr
₹7 Cr
₹9 Cr
₹2 Cr
₹7 Cr
-₹92 L
₹6 Cr
—
₹62 L
₹1 Cr
₹19 L
₹74 L
₹3 Cr
₹19 Cr
₹7 Cr
—
₹21 Cr
₹9 Cr
₹12 Cr
₹2 Cr
₹2 Cr
₹3 Cr
₹15,000
₹17 Cr
—
₹2 Cr
₹42 L
-₹27 L
₹14,000
₹17 L
₹2 Cr
-₹64 L
₹19 Cr
₹47
₹47

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2025
-₹2 Cr
-₹9 L
₹1 Cr
-₹1 Cr
-₹1 Cr
-₹10 Cr
₹1 Cr
-₹9 Cr
₹9 Cr
-₹27 L

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)0.00
Volume (₹)0.00
High (₹)0.00
Upper Circuit120.75
Low (₹)0.00
Lower Circuit109.25
Prev Close115.00
52W High (₹)218.20
Price115.00
52W Low (₹)113.70

Share Market Cap & Key Ratios Overview

M.Cap (₹)22.02 Cr
Div. Yield (%)0.00
PE Ratio0.00
Debt to Equity0.80
Price to Book3.49
Book Value46.93
EPS (TTM)-8.74
Face Value10.00
ROE (%)-26.36

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
KPRMILL-ANSE
PAGEIND-ANSE
WELSPUNLIV-ANSE
VTL-ANSE
ARVIND-ANSE
MANYAVAR-ANSE
PGIL-ANSE
ICIL-ANSE
SWANCORP-ANSE
GARFIBRES-ANSE
SKYBIOTECH-XNSE
LTP
1W Low
1W High
Market cap (₹)
1174.45+59.45 (5.33%)
1109.20
1174.45
39,613Cr
35680+1319.7 (3.84%)
34985
37796.30
39,310Cr
265.9+46.7 (21.30%)
221.40
266.65
23,931Cr
522+35.3 (7.25%)
485.40
522.30
14,779Cr
507.05+15.9 (3.24%)
488
509.95
13,643Cr
499.9+21.7 (4.54%)
478.55
507.30
12,059Cr
1305.1+116 (9.76%)
1185.50
1305.10
11,780Cr
479.35+36.55 (8.25%)
439.05
481
9,254Cr
243.95+15.8 (6.93%)
231.10
246.60
7,606Cr
742.35+0.6 (0.08%)
727.70
765
7,237Cr
115-1 (-0.86%)
113.70
117.15
22Cr

Skybiotech Healthcare Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹-₹46.4Lakh; with other income of ₹6.1Lakh, profit before interest and tax came to ₹-₹57Lakh. Interest expense was ₹40000 cr; PBT before exceptional items stood at ₹-₹57.4Lakh. Cost mix (full year): raw materials ₹3.67Cr; employee cost ₹1.96Cr; depreciation ₹10.6Lakh; other expenses ₹1.02Cr. Basis: consolidated annual results.

Skybiotech Healthcare Ltd Quaterly Results Key Takeaways

Skybiotech Healthcare Ltd reported ₹49.3Lakh total income from operations in Jun 2026, softer than ₹1.83Cr in Mar 2026 but higher than ₹2.39Cr in Jun 2025. Operating profit (before other income, interest and exceptional items) was ₹-₹46.4Lakh; with other income of ₹6.1Lakh, profit before interest and tax came to ₹-₹57Lakh. Interest expense was ₹40000 cr, taking profit before tax to ₹-₹57.4Lakh. After tax of ₹0 cr, profit after tax stood at ₹-₹57.4Lakh (vs ₹-₹30.4Lakh in Mar 2026 and ₹-₹1.8Lakh in Jun 2025).